Table 3.

Analysis of Prognostic Factors Among Patients with AML^a

Factor	N	3-year EFS ± SE (%)	P value	3-year OS ± SE(%)	P valueb
Gender			0.87		0.69
Female	95	63.2 ± 5.8		71.9 ± 5.4
Male	121	62.8 ± 5.8		70.4 ± 5.4
Race			0.07		0.12
Black	41	53.4 ± 10.1		61.0 ± 10.2
White	151	62.6 ± 5.0		70.7 ± 4.6
Other	24	82.6 ± 8.6		91.0 ± 6.4
Age (years)			0.20		0.40
<10	112	66.3 ± 5.3		74.1 ± 4.9
≥ 10	104	59.3 ± 6.5		67.9 ± 6.0
WBC count			0.57		0.80
< 50	151	62.4 ± 4.7		71.5 ± 4.4
≥ 50	65	64.3 ± 8.2		70.1 ± 7.5
Induction I MRD			<0.001		<0.001
< 0.1%	128	73.6 ± 5.0		80.5 ± 4.5
≥ 0.1%	74	43.1 ± 6.9		54.1 ± 6.9
Induction I MRD			<0.001		<0.001
< 0.1%	128	73.6 ± 5.0		80.5 ± 4.5
0.1 to < 1%	24	65.9 ± 11.6		74.3 ± 10.9
≥ 1%	50	32.1 ± 7.6		44.5 ± 8.0
FLT3-ITD			0.002		0.004
Present	28	39.3 ± 12.5		47.6 ± 12.2
Absent	173	67.6 ± 4.4		75.2 ± 4.1
CBF leukemia			<0.001		<0.001
Present	57	85.8 ± 6.1		90.6 ± 5.1
Absent	154	55.5 ± 4.9		65.6 ± 4.7
t(9;11)			0.63		0.50
Present	15	66.7 ± 14.5		80.0 ± 11.9
Absent	196	63.4 ± 4.3		71.6 ± 4.0
Other 11q23			0.19		0.08
Present	26	50.0 ± 11.8		55.9 ± 11.7
Absent	185	65.6 ± 4.4		74.6 ± 4.0
M7 without t(1;22)			0.04		0.003
Present	18	36.5 ± 11.9		44.0 ± 12.4
Absent	177	67.0 ± 4.5		75.5 ± 4.1

^aExcluding patients with mixed-lineage leukemia

^bP values are from a 10,000 permutation Monte Carlo approximation to the exact log-rank test.

Abbreviations: EFS, event-free survival; OS, overall survival; WBC, white blood cell; ITD, internal tandem duplication